Rinri Therapeutics, a UK biotech developing a novel cell-based therapy to restore hearing, has appointed Dr. Terri Gaskell as Chief Technology Officer (CTO) and member of the executive team.
Gaskell brings over 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell and gene-based therapies.
She joins Sheffield-headquartered Rinri from the UK Cell and Gene Therapy Catapult (CGTC) where she worked for more than seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure. Her role there also included advising academics and small companies on the development of advanced therapies.
Gaskell has previously held senior roles at Cell Guidance Systems and Cellartis AB (now Takara Bio Europe AB) where she was focussed on the development of processes for the expansion and differentiation of pluripotent stem cells for therapeutic use and drug discovery.
Gaskell received her Bachelor of Science (BSc.) (Hons) in Biochemistry from the University of Dundee and holds a PhD in Cell and Molecular Biology from the University of Edinburgh.